Nephrologists jumped on the GLP-1 bandwagon well before Novo Nordisk won FDA approval for Ozempic in chronic kidney disease ...
Shares of Novo Nordisk ( NVO 4.37%) were moving higher on Wednesday. The company's stock gained 4.9% as of 1:50 p.m. ET, but ...
Ozempic, or semaglutide, can now be used to reduce the risk of worsening kidney disease or kidney failure in adults with type ...
In its outlook for 2025, Novo Nordisk has predicted 'continued periodic supply constraints and related drug shortage ...
Novo Nordisk's CEO took a $1.5 million pay cut in 2024 as the pharma giant's share price tanked and it missed profit and DEI ...
The company’s shares rose as investors breathed a sigh of relief on strong sales growth and guidance, despite ongoing ...
Donald Trump's renewed push to take control of Greenland is setting off a high-stakes showdown with Denmark, a small country ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback